Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish
newsdepo.com
The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish
The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs. Read more